Table 2.
Clinical characteristic according to median value of PTX3 at 24 h after PCI.
| PTX3 < 4.384 ng/mL (n = 299) | PTX3 > 4.384 ng/mL (n = 297) | P value | |
|---|---|---|---|
| Age (years) | 66.27 ± 8.5 | 65.53 ± 7.8 | 0.269 |
| Male, n (%) | 242 (80.9) | 225 (75.8) | 0.136 |
| CCSA class > II, n (%) | 86 (28.8) | 98 (33.0) | 0.288 |
| LVEF < 50%, n (%) | 76 (25.4) | 102 (34.3) | 0.020 |
| Diabetes mellitus, n (%) | 38 (12.7) | 54 (18.2) | 0.070 |
| Hypertension, n (%) | 163 (54.5) | 156 (52.5) | 0.408 |
| Hyperlipidemia, n (%) | 94 (31.4) | 84 (28.3) | 0.726 |
| Current smoking, n (%) | 98 (32.8) | 98 (33.0) | 0.248 |
| PTX3 before PCI (ng/mL) | 3.11 ± 0.62 | 3.13 ± 0.64 | 0.699 |
| cTnI (ng/mL) | 0.205 ± 0.11 | 0.251 ± 0.16 | 0.000 |
| HsCRP (ng/mL) | 3.045 ± 1.12 | 3.496 ± 1.12 | 0.000 |
| In-hospital therapy | |||
| Aspirin, n (%) | 299 (100) | 297 (100) | |
| Clopidogrel, n (%) | 299 (100) | 297 (100) | |
| β-Blockers, n (%) | 238 (79.6) | 227 (76.4) | 0.374 |
| ACE-I or ARB, n (%) | 272 (91.0) | 260 (87.5) | 0.188 |
| Statins, n (%) | 299 (100) | 297 (100) | |
| Types of DES | |||
| Sirolimus, n (%) | 197 (65.9) | 193 (65.0) | 0.863 |
| Zotarolimus, n (%) | 66 (22.1) | 64 (21.5) | 0.921 |
| Paclitaxel, n (%) | 29 (9.7) | 34 (11.4) | 0.508 |
| Others, n (%) | 7 (2.3) | 6 (2.0) | 0.999 |
| Multiple stents, n (%) | 105 (19.5) | 133 (32.9) | 0.024 |
Abbreviations as in Table 1.